Welcome to our dedicated page for Sonendo news (Ticker: SONX), a resource for investors and traders seeking the latest updates and insights on Sonendo stock.
Sonendo Inc (SONX) is a leader in dental technology innovation, specializing in advanced endodontic solutions through its multisonic ultracleaning systems. This page aggregates all verified corporate announcements, financial disclosures, and clinical developments related to SONX.
Key updates include quarterly earnings reports, regulatory filings, product launch details, and partnership announcements. Investors gain insights into business performance while dental professionals track technological advancements in minimally invasive root canal therapy.
Regular updates cover clinical study results, intellectual property milestones, and operational expansions. All content is sourced from official releases to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to SONX's evolving position in dental technology. Check back frequently to stay informed about developments impacting both clinical practice and investment considerations.
Sonendo (NYSE: SONX), a leader in dental technology, announces further investments in the specialty of endodontics, focusing on clinical training and education. Since late-2020, Sonendo has supported over 20 endodontic residency programs, training approximately 75 residents to utilize its GentleWave® System, which offers a less painful alternative to traditional root canal treatments. The company is also actively involved in research, with 18 projects ongoing, and sponsors the American Association of Endodontists. In 2022, Sonendo organized over 130 professional education events across North America to enhance clinician knowledge.
Sonendo, Inc. (NYSE: SONX) will release its financial results for Q4 and full year 2022 on March 8, 2023, following market close. A conference call will be held at 1:30 p.m. Pacific Time to discuss these results. Investors can participate by calling (844) 200-6205 or (929) 526-1599, using access code 340170. A live audio webcast will also be available on the company's investor website, with an archived recording accessible for at least 90 days. Sonendo is known for its GentleWave® System, which treats tooth decay using innovative technology to enhance clinical outcomes and improve dental practice workflows.
Sonendo, a dental technology company, has launched a new brand campaign and website, reaffirming its commitment to endodontics and enhancing patient care. The campaign showcases clinicians utilizing the GentleWave System, emphasizing their role in advancing root canal procedures. With over one million patients treated, the campaign aims to change misconceptions about root canal therapy. The company also offers educational programs and marketing support for clinicians. CEO Bjarne Bergheim highlighted the importance of simplifying complex procedures to improve patient experiences.
Sonendo, Inc. (NYSE: SONX) announced that its subsidiary, PIPStek LLC, has filed a patent infringement lawsuit against BIOLASE, Inc. in the U.S. District Court for Delaware. The suit asserts that BIOLASE's Waterlase laser infringes on two patents owned by PIPStek. Sonendo acquired PIPStek in 2017, securing its intellectual property, which includes dental laser technologies. CEO Bjarne Bergheim emphasized their commitment to protect intellectual property and expressed confidence in a favorable court ruling.
Sonendo, a dental technology leader, reported Q3 2022 financials with total revenue of $9.8 million, up 25% from Q3 2021. Consumable revenue reached $4.8 million, marking a 30% increase year-over-year. The GentleWave install base grew to approximately 935 units. A private financing round yielded $63 million. However, the gross margin declined to 24%, and the company reported a loss from operations of $14.6 million. Full-year 2022 revenue guidance is $40.5 million to $42.5 million, reflecting 22%-28% growth.
Sonendo, Inc. (NYSE: SONX), a dental technology leader, will participate in the Stifel 2022 Healthcare Conference on November 15 at 10:55 a.m. Eastern Time. An audio webcast will be available on their website. Sonendo focuses on innovative treatments for tooth decay via the patented GentleWave® System, offering less invasive procedures with improved clinical outcomes. The company also owns TDO Software, enhancing dental practice management.
Sonendo has received Health Canada regulatory approval for its GentleWave G4 System, aimed at improving the treatment of tooth decay in Canada. This next-generation technology enhances user experience with a simplified workflow and advanced features, including battery backup and multi-operatory connectivity. A recent clinical trial showed that 99.5% of patients reported no pain during procedures using GentleWave Technology. This approval marks a significant expansion of Sonendo’s product offerings in Canada, reinforcing its commitment to endodontic practices.
Sonendo, Inc. (NYSE: SONX) is set to release its financial results for Q3 2022 on November 9, 2022, after market close. The management will hold a conference call at 1:30 p.m. PT to discuss results. The GentleWave® System, developed by Sonendo, aims to enhance dental procedures by cleaning tooth decay without removing tooth structure, offering improved patient outcomes. The company also owns TDO® Software, which streamlines endodontic practice management.
FAQ
What is the current stock price of Sonendo (SONX)?
What is the market cap of Sonendo (SONX)?
